For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Three Nabbed over Counterfeit APIs for Sleeping Pill: Tokyo Metropolitan Police
February 21, 2022
- BMS Japan to Kick Off Workplace Booster Program in March
February 18, 2022
- Parmodia-Deberza Combo Improves NASH in Mice: Kowa/Univ. of Tokyo
February 18, 2022
- AstraZeneca to Discontinue Bydureon, Zestril amid Weak Sales
February 18, 2022
- Chugai Claims 1st-Ever Title in Japan Pharma Market in 2021 on Brisk Oncologic Performance: IQVIA
February 18, 2022
- Sawai to Launch Teribone Generic as Court Invalidates Patents; Asahi Kasei to Challenge Ruling
February 17, 2022
- GSK Launches Benlysta Observational Study in SLE Patients with History of Lupus Nephritis
February 17, 2022
- Healios Plans Preapplication Consultation with PMDA on MultiStem as Early as March
February 17, 2022
- GMP Issues Likely to Trigger Ozempic Supply Restrictions in Japan: Novo
February 16, 2022
- Padcev Shows 36.4% Pathologic Complete Response in Bladder Cancer
February 16, 2022
- Opdivo Approved for 5 New Indications in South Korea
February 16, 2022
- Bayer Employee Loses in Damage Suit over Xarelto Scandal
February 15, 2022
- Pharma Officials Air Hopes and Concerns as Japan Moves to Enhance Supply Chain for Economic Security
February 15, 2022
- MSD Japan Boosts COVID-19 Pill Supply to 800,000 Courses by March
February 15, 2022
- Taiho Files TS-1 for Adjuvant Chemo in Breast Cancer in Japan
February 15, 2022
- Meiji Ditches Ziprasidone Schizophrenia Program in Japan
February 15, 2022
- Chugai to Integrate 2 Chinese Subsidiaries in April
February 15, 2022
- Otsuka’s 4 Global Brands Fare Well to Hit 2023 Target 2 Years Earlier
February 14, 2022
- Chugai Joins Top Ranks in Japan Sales on Ronapreve Boon, Roche Collaboration
February 14, 2022
- Sanofi Files NDA for Rare Blood Disease Drug in Japan
February 14, 2022
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…